A Specific TRNA Half, 5'tiRNA-His-GTG, Responds to Hypoxia Via the HIF1α/ANG Axis and Promotes Colorectal Cancer Progression by Regulating LATS2
Overview
Affiliations
Background: Currently, tRNA-derived small RNAs (tsRNAs) are recognized as a novel and potential type of non-coding RNAs (ncRNAs), which participate in various cellular processes and play an essential role in cancer progression. However, tsRNAs involvement in colorectal cancer (CRC) progression remains unclear.
Methods: Sequencing analyses were performed to explore the tsRNAs with differential expression in CRC. Gain- and loss-of functions of 5'tiRNA-His-GTG were performed in CRC cells and xenograft tumor to discover its role in the progression of CRC. Hypoxia culture and hypoxia inducible factor 1 subunit alpha (HIF1α) inhibitors were performed to uncover the biogenesis of 5'tiRNA-His-GTG. The regulation of 5'tiRNA-His-GTG for large tumor suppressor kinase 2 (LATS2) were identified by luciferase reporter assay, western blot, and rescue experiments.
Results: Here, our study uncovered the profile of tsRNAs in human CRC tissues and confirmed a specific tRNA half, 5'tiRNA-His-GTG, is upregulated in CRC tissues. Then, in vitro and in vivo experiments revealed the oncogenic role of 5'tiRNA-His-GTG in CRC and found that targeting 5'tiRNA-His-GTG can induce cell apoptosis. Mechanistically, the generation of 5'tiRNA-His-GTG seems to be a responsive process of tumor hypoxic microenvironment, and it is regulated via the HIF1α/angiogenin (ANG) axis. Remarkably, LATS2 was found to be an important and major target of 5'tiRNA-His-GTG, which renders 5'tiRNA-His-GTG to "turn off" hippo signaling pathway and finally promotes the expression of pro-proliferation and anti-apoptosis related genes.
Conclusions: In summary, the findings revealed a specific 5'tiRNA-His-GTG-engaged pathway in CRC progression and provided clues to design a novel therapeutic target in CRC.
New insights into tRNA-derived small RNAs in human digestive diseases.
Liu Y, Chen F, Zhang F, Ye Y, Su Y, Liu Y Mol Biol Rep. 2025; 52(1):295.
PMID: 40063289 DOI: 10.1007/s11033-025-10393-7.
Glogovitis I, DAmbrosi S, Antunes-Ferreira M, Chiogna M, Yahubyan G, Baev V Noncoding RNA. 2025; 11(1).
PMID: 39997617 PMC: 11858735. DOI: 10.3390/ncrna11010017.
Identification and potential mechanism of a novel gastric cancer suppressor tRF-24-6VR8K09LE9.
Tang Y, Ni K, Jin K, Feng W, Ju S, Jing R Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 39992418 DOI: 10.1007/s00210-025-03914-5.
Zhang B, Pan Y, Li Z, Hu K J Transl Med. 2025; 23(1):51.
PMID: 39806419 PMC: 11727791. DOI: 10.1186/s12967-025-06109-x.
Zhang Y, Ma Y, Ji Y, Jiang Y, Li D, Mu W Cell Commun Signal. 2025; 23(1):18.
PMID: 39794828 PMC: 11721595. DOI: 10.1186/s12964-024-02013-x.